BioCentury
ARTICLE | Clinical News

Telatinib: Additional Phase II data

December 12, 2011 8:00 AM UTC

An analysis of serum samples from 28 evaluable patients in the open-label, U.S. and Spanish Phase II TEL0805 trial showed that both PFS and OS were significantly longer in patients who had a >=33% reduction in serum levels of the soluble form of the VEGF receptor 2 ( KDR/Flk-1; VEGFR-2) biomarker following treatment with twice-daily oral telatinib plus capecitabine and cisplatin. Specifically, patients with a greater reduction in soluble VEGFR-2 had a PFS of 11.6 months vs. 4.7 months for patients with a smaller reduction in levels of the biomarker. Additionally, OS has not yet been reached in patients with a greater reduction in soluble VEGFR-2 compared to 7.6 months for patients with a smaller reduction in levels of the biomarker. ACT Biotech said that soluble VEGFR-2 could be used as a quantitative biomarker to identify patients that best respond to telatinib. The company plans to integrate the biomarker in upcoming trials of the compound. Data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. ...